Angiopoietin-1/Tie2 signaling pathway contributes to the therapeutic effect of thymosin β4 on diabetic peripheral neuropathy.

Wang L, Chopp M, Szalad A, Lu X, Lu M, Zhang T, Zhang ZG

Neuroscience research13 Oct 2018Cited by 6 (Europe PMC)

PMID30326249PMCIDPMC6462258DOI10.1016/j.neures.2018.10.005PepBankPUB-30326249

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

01AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism
In db/db mice with diabetic peripheral neuropathy, neutralizing anti-Tie2 antibody given with Tβ4 attenuated the Tβ4 improvement in motor nerve conduction velocity compared with Tβ4 alone.
In plain wordsIn diabetic mice, blocking Tie2 reduced the nerve speed benefit of thymosin beta‑4 compared with thymosin beta‑4 alone.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseMotor nerve conduction velocity
Study
mousen: not reported in source
db/db diabetic mice
Comparator
Tβ4 alone (no anti-Tie2 antibody)
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Administration of the neutralizing antibody against Tie2 attenuated the therapeutic effect of Tβ4 on improved diabetic peripheral neuropathy as measured by motor and sensory nerve conduction velocity and thermal hypoesthesia compared to diabetic db/db mice treated with Tβ4 only.
1 context sentence(design, population, supporting numbers)
Summary · context
Cg-m+/+Lepr^db/J (db/db) mice at age 20 weeks were treated with Tβ4 and neutralizing antibody against mouse Tie2 for 4 consecutive weeks.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3032624901
02AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism
In db/db mice with diabetic peripheral neuropathy, neutralizing anti-Tie2 antibody given with Tβ4 attenuated the Tβ4 improvement in sensory nerve conduction velocity compared with Tβ4 alone.
In plain wordsIn diabetic mice, blocking Tie2 reduced the sensory nerve speed benefit of thymosin beta‑4 compared with thymosin beta‑4 alone.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseSensory nerve conduction velocity
Study
mousen: not reported in source
db/db diabetic mice
Comparator
Tβ4 alone (no anti-Tie2 antibody)
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Administration of the neutralizing antibody against Tie2 attenuated the therapeutic effect of Tβ4 on improved diabetic peripheral neuropathy as measured by motor and sensory nerve conduction velocity and thermal hypoesthesia compared to diabetic db/db mice treated with Tβ4 only.
1 context sentence(design, population, supporting numbers)
Summary · context
Cg-m+/+Lepr^db/J (db/db) mice at age 20 weeks were treated with Tβ4 and neutralizing antibody against mouse Tie2 for 4 consecutive weeks.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3032624902
03AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism
In db/db mice with diabetic peripheral neuropathy, neutralizing anti-Tie2 antibody given with Tβ4 attenuated the Tβ4 improvement in thermal hypoesthesia compared with Tβ4 alone.
In plain wordsIn diabetic mice, blocking Tie2 reduced the heat sensation benefit of thymosin beta‑4 compared with thymosin beta‑4 alone.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseThermal hypoesthesia
Study
mousen: not reported in source
db/db diabetic mice
Comparator
Tβ4 alone (no anti-Tie2 antibody)
Outcome group
Pain · Nervous system and cognition
Source sentences
Summary
Administration of the neutralizing antibody against Tie2 attenuated the therapeutic effect of Tβ4 on improved diabetic peripheral neuropathy as measured by motor and sensory nerve conduction velocity and thermal hypoesthesia compared to diabetic db/db mice treated with Tβ4 only.
1 context sentence(design, population, supporting numbers)
Summary · context
Cg-m+/+Lepr^db/J (db/db) mice at age 20 weeks were treated with Tβ4 and neutralizing antibody against mouse Tie2 for 4 consecutive weeks.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3032624903
04AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism
In db/db mice, neutralizing anti-Tie2 antibody abolished the Tβ4-induced increase in microvascular density in the sciatic nerve.
In plain wordsIn diabetic mice, blocking Tie2 removed the increase in nerve blood vessel density seen with thymosin beta‑4.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseMicrovascular density in sciatic nerve
Study
mousen: not reported in source
db/db diabetic mice
Comparator
Tβ4 alone (no anti-Tie2 antibody)
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Histopathological analysis revealed that the neutralizing antibody against Tie2 abolished Tβ4-increased microvascular density in sciatic nerve and intraepidermal nerve fiber density, which were associated with suppression of Tβ4-upregulated occludin expression and Tβ4-reduced protein levels of nucle…
1 context sentence(design, population, supporting numbers)
Summary · context
Cg-m+/+Lepr^db/J (db/db) mice at age 20 weeks were treated with Tβ4 and neutralizing antibody against mouse Tie2 for 4 consecutive weeks.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3032624904
05AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism
In db/db mice, neutralizing anti-Tie2 antibody abolished the Tβ4-induced increase in intraepidermal nerve fiber density.
In plain wordsIn diabetic mice, blocking Tie2 removed the increase in skin nerve fibers seen with thymosin beta‑4.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseIntraepidermal nerve fiber density
Study
mousen: not reported in source
db/db diabetic mice
Comparator
Tβ4 alone (no anti-Tie2 antibody)
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Histopathological analysis revealed that the neutralizing antibody against Tie2 abolished Tβ4-increased microvascular density in sciatic nerve and intraepidermal nerve fiber density, which were associated with suppression of Tβ4-upregulated occludin expression and Tβ4-reduced protein levels of nucle…
1 context sentence(design, population, supporting numbers)
Summary · context
Cg-m+/+Lepr^db/J (db/db) mice at age 20 weeks were treated with Tβ4 and neutralizing antibody against mouse Tie2 for 4 consecutive weeks.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3032624905
06AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism
In db/db mice, neutralizing anti-Tie2 antibody was associated with suppression of Tβ4-upregulated occludin expression.
In plain wordsIn diabetic mice, blocking Tie2 was linked to lower occludin levels that thymosin beta‑4 had raised.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseOccludin expression
Study
mousen: not reported in source
db/db diabetic mice
Comparator
Tβ4 alone (no anti-Tie2 antibody)
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Histopathological analysis revealed that the neutralizing antibody against Tie2 abolished Tβ4-increased microvascular density in sciatic nerve and intraepidermal nerve fiber density, which were associated with suppression of Tβ4-upregulated occludin expression and Tβ4-reduced protein levels of nucle…
1 context sentence(design, population, supporting numbers)
Summary · context
Cg-m+/+Lepr^db/J (db/db) mice at age 20 weeks were treated with Tβ4 and neutralizing antibody against mouse Tie2 for 4 consecutive weeks.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3032624906
07AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism
In db/db mice, neutralizing anti-Tie2 antibody was associated with suppression of the Tβ4-induced reduction in NF-κB protein levels.
In plain wordsIn diabetic mice, blocking Tie2 was linked to loss of the NF-κB reduction seen with thymosin beta‑4.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseNF-κB protein level
Study
mousen: not reported in source
db/db diabetic mice
Comparator
Tβ4 alone (no anti-Tie2 antibody)
Outcome group
Inflammation markers · Nervous system and cognition
Source sentences
Summary
Histopathological analysis revealed that the neutralizing antibody against Tie2 abolished Tβ4-increased microvascular density in sciatic nerve and intraepidermal nerve fiber density, which were associated with suppression of Tβ4-upregulated occludin expression and Tβ4-reduced protein levels of nucle…
1 context sentence(design, population, supporting numbers)
Summary · context
Cg-m+/+Lepr^db/J (db/db) mice at age 20 weeks were treated with Tβ4 and neutralizing antibody against mouse Tie2 for 4 consecutive weeks.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3032624907
08AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism
In db/db mice, neutralizing anti-Tie2 antibody was associated with suppression of the Tβ4-induced reduction in VCAM1 protein levels.
In plain wordsIn diabetic mice, blocking Tie2 was linked to loss of the VCAM1 reduction seen with thymosin beta‑4.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseVCAM1 protein level
Study
mousen: not reported in source
db/db diabetic mice
Comparator
Tβ4 alone (no anti-Tie2 antibody)
Outcome group
Inflammation markers · Nervous system and cognition
Source sentences
Summary
Histopathological analysis revealed that the neutralizing antibody against Tie2 abolished Tβ4-increased microvascular density in sciatic nerve and intraepidermal nerve fiber density, which were associated with suppression of Tβ4-upregulated occludin expression and Tβ4-reduced protein levels of nucle…
1 context sentence(design, population, supporting numbers)
Summary · context
Cg-m+/+Lepr^db/J (db/db) mice at age 20 weeks were treated with Tβ4 and neutralizing antibody against mouse Tie2 for 4 consecutive weeks.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3032624908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.